The importance of imaging studies to monitor treatment with novel ar-targeted agents in metastatic castration resistant prostate cancer (mCRPC)

Category Primary study
JournalJournal of Urology
Year 2017
This article has no abstract
Epistemonikos ID: ac464739de76f9a305bc8c357030c258453a0c97
First added on: Feb 08, 2025